Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Viragen, Inc. (AMEX:VRA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials
Location
865 SW 78th Avenue, Suite 100
Plantation, FL 33324
Phone: (954) 233-8746
Fax: (954) 233-1414
Email: dcalder@viragen.com
Employees (last reported count): 42
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 8%
·Institutional: 2% (2% of float)
(22 institutions)
·Net Inst. Buying: 877.0K shares (+34.13%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Viragen, Inc. researches, develops and manufactures pharmaceutical drugs including natural human interferon and human monoclonal antibodies for the treatment of many life-threatening diseases such as hepatitis C, multiple sclerosis and cancer. In addition to developing proprietary drugs, Viragen is engaged in a project designed to deliver efficient, cost-effective alternatives for the large-scale production of protein-based drugs. Viragen holds the exclusive license to commercialize Avian Transgenic Production Technology granted by the Roslin Institute in Scotland, which created "Dolly the Sheep." The Avian Project is designed to produce protein-based drugs, including monoclonal antibodies to fight cancer, inside the eggs of transgenic chickens. Viragen's current collaborative partners include The Roslin Institute, Memorial Sloan-Kettering Cancer Center, The National Institutes of Health (NIH), The United Kingdom's Cancer Research Campaign, Pall Corporation and America's Blood Centers.
More from Market Guide: Expanded Business Description

Financial Summary
Viragen, Inc. engages in the research, development, and manufacture of immunological products, particularly human leukocyte interferon for antiviral and therapeutic applications. For the nine months ended 3/31/01, revenues totaled $604 thousand, up from $62 thousand. Net loss applicable to Common decreased 18% to $7.4 million. Revenues reflect increased interest income. Net loss was partially offset by higher R&D costs due to development, scale-up and clinical trial costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Gerald Smith, 69
Chairman, Pres, and CEO
$282K$369K
Robert Zeiger, 56
Vice Chairman
--  --  
Dennis Healey, 52
CFO, Treasurer, Exec. VP, Director
252K22K
D. Magnus Nicolson, Ph.D., 40
COO
170K42K
Melvin Rothberg, 53
Exec. VP
160K144K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:VRAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 18-Apr-2001
$1.02 
Recent Price$1.45 
52-Week High
on 6-Dec-2000
$2.875
Beta0.40 
Daily Volume (3-month avg)128.4K
Daily Volume (10-day avg)88.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+0.8%
52-Week Change
relative to S&P500
+35.3%
Share-Related Items
Market Capitalization$142.7M
Shares Outstanding98.4M
Float90.5M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.13 
Earnings (ttm)-$0.12 
Earnings (mrq)-$0.03 
Sales (ttm)$0.01 
Cash (mrq)$0.09 
Valuation Ratios
Price/Book (mrq)11.33 
Price/EarningsN/A 
Price/Sales (ttm)186.66 
Income Statements
Sales (ttm)$713.0K
EBITDA (ttm)-$9.84M
Income available to common (ttm)-$10.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter31-Mar-2001
Management Effectiveness
Return on Assets (ttm)-86.01%
Return on Equity (ttm)-100.15%
Financial Strength
Current Ratio (mrq)6.80 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$9.05M
Short Interest
As of 8-Aug-2001
Shares Short192.0K
Percent of Float0.2%
Shares Short
(Prior Month)
0 
Short Ratio1.07 
Daily Volume180.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.